A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

BACKGROUND: Triweekly capecitabine plus irinotecan (XELIRI) is not completely regarded as a valid substitute for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. We conducted a phase I/II study to assess the effi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Drug Des Devel Ther
Prif Awduron: Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2015
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365742/
https://ncbi.nlm.nih.gov/pubmed/25834402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S80449
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg